Rapid resolution of erythrodermic atopic dermatitis with upadacitinib: A case report.
Mysa SaadMarina GuirguisCamille HammReetesh BosePublished in: SAGE open medical case reports (2024)
Atopic dermatitis is a chronic inflammatory skin disease that may progress to erythroderma in severe cases. Biologic agents such as dupilumab have recently become the mainstay of systemic treatment for moderate-to-severe cases, yet many patients remain refractory to therapy. Here, we present a case of erythrodermic atopic dermatitis, resistant to prednisone and dupilumab, with remarkably rapid achievement of remission following treatment with upadacitinib, an oral selective Janus kinase 1 inhibitor.
Keyphrases
- atopic dermatitis
- end stage renal disease
- ejection fraction
- rheumatoid arthritis
- chronic kidney disease
- oxidative stress
- early onset
- drug induced
- peritoneal dialysis
- systemic lupus erythematosus
- mesenchymal stem cells
- single molecule
- loop mediated isothermal amplification
- replacement therapy
- ulcerative colitis
- wound healing